EMFLAZA® (deflazacort) is a corticosteroid that demonstrates anti-inflammatory and immunosuppressant effects.
EMFLAZA® is indicated for the treatment of Duchenne muscular dystrophy in patients 2 years of age and older (download EMFLAZA® label & prescribing information).
For additional resources regarding eligibility and access, view PPMD’s Insurance Access & Coverage Roadmap.
On March 27, 2020, PTC Therapeutics shared an additional update on the availability of EMFLAZA during COVID-19.
This program is sponsored by PTC Therapeutics.
PTC Therapeutics Presents at the PPMD 2021 Virtual Annual ConferencePre-recorded content for PPMD's 2021 Virtual Annual Conference On-Demand Library
PTC Therapeutics Presents at the PPMD 2019 Annual Conference
Webinar: An Update on CorticosteroidsPPMD and Dr. John Brandsema hosted a webinar on October 24, 2018 to discuss the current guidelines for steroid use in Duchenne muscular dystrophy, emerging data, and best practices.